Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Ling

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Drug and Alcohol Dependence|May 30, 2008
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawalElmer Yu, Karen Miotto, Evaristo Akerele, et al.
Contemporary Clinical Trials|August 14, 2016
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationaleJoshua D Lee, Edward V Nunes, Patricia Novo Mpa, et al.
The New England Journal of Medicine|September 5, 2003
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxonePaul J Fudala, T Peter Bridge, Susan Herbert, et al.
Drug and Alcohol Dependence|August 28, 2012
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trialAndrew J Saxon, Walter Ling, Maureen Hillhouse, et al.
Archives of General Psychiatry|January 7, 2004
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusersEdythe D London, Sara L Simon, Steven M Berman, et al.
Journal of Substance Abuse Treatment|March 24, 2010
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?Edward V Nunes, Samuel Ball, Robert Booth, et al.
European Journal of Clinical Pharmacology|February 26, 2022
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin geneDavid A Nielsen, Robrina Walker, David P Graham, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2007
Bupropion for the treatment of methamphetamine dependenceAhmed M Elkashef, Richard A Rawson, Ann L Anderson, et al.
The New England Journal of Medicine|January 26, 2021
Bupropion and Naltrexone in Methamphetamine Use DisorderMadhukar H Trivedi, Robrina Walker, Walter Ling, et al.
The American Journal on Addictions|June 19, 2004
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experienceLeslie Amass, Walter Ling, Thomas E Freese, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Drug and Alcohol Dependence|May 30, 2008
A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawalElmer Yu, Karen Miotto, Evaristo Akerele, et al.
Contemporary Clinical Trials|August 14, 2016
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationaleJoshua D Lee, Edward V Nunes, Patricia Novo Mpa, et al.
The New England Journal of Medicine|September 5, 2003
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxonePaul J Fudala, T Peter Bridge, Susan Herbert, et al.
Drug and Alcohol Dependence|August 28, 2012
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trialAndrew J Saxon, Walter Ling, Maureen Hillhouse, et al.
Archives of General Psychiatry|January 7, 2004
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusersEdythe D London, Sara L Simon, Steven M Berman, et al.
Journal of Substance Abuse Treatment|March 24, 2010
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?Edward V Nunes, Samuel Ball, Robert Booth, et al.
European Journal of Clinical Pharmacology|February 26, 2022
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin geneDavid A Nielsen, Robrina Walker, David P Graham, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 22, 2007
Bupropion for the treatment of methamphetamine dependenceAhmed M Elkashef, Richard A Rawson, Ann L Anderson, et al.
The New England Journal of Medicine|January 26, 2021
Bupropion and Naltrexone in Methamphetamine Use DisorderMadhukar H Trivedi, Robrina Walker, Walter Ling, et al.
The American Journal on Addictions|June 19, 2004
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experienceLeslie Amass, Walter Ling, Thomas E Freese, et al.
Pageof 17